G1 Therapeutics Reports P-III Trial (PRESERVE 1) Results of Trilaciclib for Metastatic Colorectal Cancer
Shots:
- The P-III trial (PRESERVE 1) evaluating trilaciclib + FOLFOXIRI and Avastin vs PBO in 326 patients. The trial met its co-primary EPs i.e., reduction in the occurrence of sev. neutropenia during induction (1% vs 20%) & duration of sev. neutropenia in cycles 1-4 (0.1 vs 1.3 days)
- Clinical reduction in the rate of CT-induced diarrhea, incl. a 50% & 30% reduction in the rate of grade 3/4 & any grade diarrhea, respectively over PBO, patients experienced fewer CT dose reductions & delays while the secondary measures of myeloprotection also favored trilaciclib, incl. reductions in Febrile neutropenia (0% vs 5%) & ESA administration (3% vs 7%)
- Early anti-tumor efficacy data, incl. ORR (50% vs 60%) & preliminary measures of survival favored the PBO, the company has decided to discontinue its research due to a lack of responses
Ref: GlobeNewswire | Image: BioSpace
Related News:- G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
